Spotitearly, a biotech startup that uses AI and dogs to detect cancer using a home test, announced the launch on the American market with $ 20.3 million in financing.
The company has received financing from Menomedin VC, Jeff Swartz (former CEO of Timberland), Avishai Abrahami (CEO of Wix.com), Hanaco VC and others.
In addition, SpotiTearly received subsidies, including one of the Bird Foundation, which finances research and development between Israeli and American companies.
The company also announced the appointments of the American advisers on his board, including Dr. David Sidransky, an expert in the detection of molecular genetic cancer; Jonathan Fleming, teacher at MIT and a Medtech Investor; and Dr. Len Lichtenfeld, former CEO of the American Cancer Society. Lichtenfeld will also serve as Chief Medical Officer of Spotitearly.
What it does
SpotiTearly is a cancer screening company that uses AI and fangs to analyze volatile organic compounds in an AdemMonster to detect cancer at an early stage.
A person collects an Adem sample with a home test. The company then uses the Geurdetection of trained fangs and its lucid AI technology, which analyzes thousands of data points on the physical and behavioral signals of a dog, to detect cancer at an early stage.
The test, which will be made available in the US in the US in 2026, can help detect four types of cancer: chest, colorectal, prostate and lung.
The company said that one study About his technology, published in Natureshowed an accuracy percentage of 94% when detecting cancer.
Spotitearly will use the money to scale its reach in the US and to improve its cancer detection technology. It also announced the opening of its Serie A Finance Round in addition to the launch in the US
“Only 14 percent Of the American population, cancer is diagnosed through a preventive screening method; Patients have a better chance of Get the diagnosis of cancer on first aid – A clear indication of systematic problems within our health care system, which has more often given priority to treatment over prevention, “said Shlomi Madar, CEO of Spotitearly, said MobiHealthNews In an e -mail.
“By making early detection and diagnosis of cancer more accessible, more affordable and less invasive, we are positioned to improve the survival rates for millions of Americans, and wider, help to proactively move the American health care system of a reactive model to a proactive.”
Market Snapshot
One of the earliest studies About the ability of cancer to detect cancer was published in 1989 in the Lancet, called “Sniffer dogs in the melanoma clinic?”
A more recent study“Proof of the olfactory detection of melanoma of dogs,” it turned out that dogs can detect melanoma because of “the biological or non-biological detection of volatile chemicals arising from skin lesions.”
#Spotitearly #launched #million #detect #cancer #dogs